MorphoSys AGNASDAQ: MOR

MUNICH, GERMANY / ACCESSWIRE / August 27, 2024 / MorphoSys AG today announced that its shareholders approved all resolutions proposed by the company's Management Board and Supervisory Board at its 2024 Annual General Meeting. This included the transfer of MorphoSys' minority shareholders' shares to Novartis BidCo Germany AG (hereinafter referred to as "Novartis"), the company's majority shareholder, against a cash compensation of € 68.00 per share ("merger squeeze-out").

NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating MorphoSys AG ( N asdaq : MOR ) , relating to a tender offer from Novartis BidCo AG. Under the terms of the offer, MorphoSys shareholders will receive €68.00 per share they own.

NEW YORK , July 15, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating MorphoSys AG (Nasdaq: MOR ), relating to a tender offer from Novartis BidCo AG.

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Exchange Act of 1934 (the “Exchange Act”). MorphoSys currently anticipates that it will file with the Securities and Exchange Commission (the “SEC”) a Form 25, Notification of.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of MorphoSys AG (NASDAQ: MOR) to Novartis for €68.00 per share in cash is fair to MorphoSys shareholders. Halper Sadeh encourages MorphoSys shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether MorphoSys and its board o.

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as “Novartis”) also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a.

Under the MOR-EV program, the Mullen THREE EV truck, with a suggested MSRP of $68,500, now qualifies for a Massachusetts state cash rebate of up to $15,000

MorphoSys was purchased by Novartis for EUR 2.7 billion, which represents a substantial premium compared to the share price before the announcement. The acquisition is anticipated to proceed without complications, as indicated by regulatory approvals and past successful mergers. Pelabresib, MorphoSys's top contender for treating myelofibrosis, has shown encouraging outcomes and has the potential to revolutionize the industry.

Morphosys confirmed that it still anticipates the completion of its acquisition by Novartis in the first half of this year, despite a safety concern raised by STAT News causing a drop in the company's stock price on Monday.